^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    ALK fusion

    i
    Other names: NBLST3, CD246, Anaplastic Lymphoma Kinase, Anaplastic Lymphoma Kinase (Ki-1), CD246 Antigen, Mutant Anaplastic Lymphoma Kinase, ALK, ALK Receptor Tyrosine Kinase, Anaplastic Lymphoma Receptor Tyrosine Kinase, ALK Tyrosine Kinase Receptor
    Entrez ID:
    238
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Related tests:
    2d
    Gene Fusions in Melanocytic Lesions: An Updated Comprehensive Review. (PubMed, J Pathol Transl Med)
    Early clinical evidence of TRK, ALK, and ROS1 inhibitor efficacy underscores the translational promise of fusion testing and opens avenues for personalized therapy. This review synthesizes current knowledge on the genomics, histopathology, diagnosis, and therapeutic implications of fusion-driven melanocytic neoplasms, highlighting consensus points and remaining controversies.
    Journal
    |
    BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • MAP3K8 (Mitogen-Activated Protein Kinase Kinase Kinase 8)
    |
    ALK fusion • ROS1 fusion
    2d
    Multidisciplinary Treatment of Stage III ALK+ NSCLC With Neoadjuvant Alectinib and Chemotherapy (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, Wen-zhao ZHONG
    New P2 trial
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK fusion
    |
    Alecensa (alectinib) • Piqray (alpelisib)
    3d
    Renal cell carcinoma with a novel RAB1A::ALK fusion: expanding the molecular spectrum of ALK-rearranged RCC. (PubMed, Virchows Arch)
    This report describes the clinicopathological and molecular features of the tumor, with a particular focus on the characterization of the RAB1A gene and its documented impact on carcinogenesis and prognosis across several solid malignancies. Our findings expand the molecular spectrum of ALK-RCC and emphasize the role of comprehensive molecular profiling in uropathology.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • CA9 (Carbonic anhydrase 9) • RAB1A (RAB1A, Member RAS Oncogene Family)
    |
    ALK rearrangement • ALK fusion
    3d
    A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P3, N=68, Active, not recruiting, Hoffmann-La Roche | Trial primary completion date: Dec 2026 --> Jun 2030
    Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ALK positive • ALK fusion • ROS1 fusion • ROS1 positive
    |
    PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP263) Assay
    |
    Imfinzi (durvalumab) • Rozlytrek (entrectinib) • Alecensa (alectinib)
    4d
    Epithelioid Fibrous Histiocytoma with LRRFIP1::ALK Fusion and Smooth Muscle Hyperplasia. (PubMed, Int J Surg Pathol)
    This is the first report of an LRRFIP1::ALK fusion in EFH. The influence of this fusion partner on the histological features of EFH remains undetermined.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • LRRFIP1 (LRR Binding FLII Interacting Protein 1)
    |
    ALK rearrangement • ALK fusion
    5d
    DARWIN II: Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity (clinicaltrials.gov)
    P2, N=50, Completed, University College, London | Active, not recruiting --> Completed | Trial completion date: May 2026 --> Nov 2025 | Trial primary completion date: May 2026 --> Nov 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene)
    |
    HER-2 amplification • BRAF V600 • RET fusion • ALK fusion
    |
    Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • carboplatin • Alecensa (alectinib) • Kadcyla (ado-trastuzumab emtansine)
    6d
    Surgical management of the primary tumor in stage M1a-IVA Non-Small Cell Lung Cancer. (PubMed, J Thorac Cardiovasc Surg)
    By comparing outcomes between patients managed with systemic therapy alone and those undergoing surgical intervention during treatment, this study suggests that primary tumor resection is feasible and may be associated with favorable survival outcomes in highly selected patients with stage M1a-IVA NSCLC.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR L858R • EGFR exon 19 deletion • ALK fusion
    6d
    Uterine Inflammatory Myofibroblastic Tumor: A Case Report. (PubMed, Cureus)
    Histologically, IMTs are composed of spindle myofibroblasts in a myxoid to compact stroma with an inflammatory infiltrate, and they often exhibit anaplastic lymphoma kinase (ALK) gene fusions and ALK positivity. The main treatment approach is surgical excision, with ALK inhibitors as a therapeutic option in selected cases.
    Journal
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK fusion
    7d
    BO43249: A Study to see How Well and How Safely Different Treatments Work in a Group of Patients with Non-Small Cell Lung Cancer, Chosen Based on their Biomarker Status (2024-511239-91-00)
    P1/2, N=54, Recruiting, F. Hoffmann-La Roche AG | Phase classification: P2/3 --> P1/2
    Phase classification
    |
    ALK fusion
    |
    cisplatin • carboplatin • Alecensa (alectinib) • pemetrexed
    11d
    GAIN/iCat2: The iCat2, GAIN (Genomic Assessment Informs Novel Therapy) Consortium Study (clinicaltrials.gov)
    P=N/A, N=825, Active, not recruiting, Dana-Farber Cancer Institute | Trial primary completion date: Jan 2026 --> Jun 2026
    Trial primary completion date
    |
    NTRK (Neurotrophic receptor tyrosine kinase)
    |
    ALK fusion • NTRK fusion
    13d
    Multifocal papillary thyroid carcinoma with RET p.V804M, EML4-ALK fusion, and BRAF V600E positivity. (PubMed, JCEM Case Rep)
    Histopathology confirmed multifocal PTC and a background of chronic lymphocytic thyroiditis with 23 lymph nodes negative for metastasis. This case presents heterogeneity of oncogenic drivers in PTC and the potential value of comprehensive molecular profiling in risk stratification and management.
    Journal
    |
    BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • EML4 (EMAP Like 4)
    |
    BRAF V600E • BRAF V600 • ALK fusion • ALK mutation • RET mutation • RET V804*
    16d
    Deulorlatinib (TGRX-326) in ALK gene fusion positive non-small cell lung cancer after failure of second-generation inhibitors (DRAGON): a single-arm, multicenter, phase 2 trial. (PubMed, J Thorac Oncol)
    Deulorlatinib demonstrated encouraging anti-tumor activity in patients with advanced ALK-positive NSCLC after failure of second-generation ALK inhibitors, including those with the G1202R mutation. Given its favorable safety profile, deulorlatinib represents a promising new option for this population.
    P2 data • Journal
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK positive • ALK fusion • ALK G1202R
    |
    Lorbrena (lorlatinib) • deulorlatinib (TGRX-326)